Brokerages expect Stevanato Group Spa (NYSE:STVN) to announce sales of $239.04 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Stevanato Group’s earnings. The highest sales estimate is $240.72 million and the lowest is $236.99 million. The firm is expected to issue its next earnings report on Thursday, November 18th.
On average, analysts expect that Stevanato Group will report full-year sales of $968.77 million for the current financial year, with estimates ranging from $965.47 million to $972.72 million. For the next year, analysts forecast that the company will report sales of $1.06 billion, with estimates ranging from $1.05 billion to $1.06 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Stevanato Group.
Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Thursday, August 19th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.11 by $0.04. The company had revenue of $245.77 million during the quarter, compared to the consensus estimate of $239.72 million.
NYSE STVN traded up $0.62 on Monday, reaching $28.40. 4,459 shares of the stock were exchanged, compared to its average volume of 853,188. Stevanato Group has a one year low of $16.61 and a one year high of $28.66. The firm’s 50-day moving average price is $23.54.
Stevanato Group Company Profile
Stevanato Group S.p.A. is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group S.p.A. is based in PIOMBINO DESE, Italy.
Further Reading: What is the CBOE Russell 2000® Volatility Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.